The White House released an expansive report that blames a crisis of chronic disease in children on ultraprocessed foods, chemical exposures, lack of physical activity, stress and excessive use of ...

The FDA approved Yutrepia inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension ...

Liquidia Corporation (NASDAQ:LQDA) said on Friday that the U.S. FDA has approved Yutrepia inhalation powder, a prostacyclin ...

Far removed from the negative attention such drugs used to get, the hope is that they help people find answers within ...

Shuttle-based therapies are under active development for an array of brain conditions. “It’s now abundantly clear that we can ...

many with no approved treatments. It has previously suggested that the drug could eventually become a $5 billion-a-year product which, if achieved, would help it weather the impact of patent ...

The approval follows positive results for Fabhalta in the phase 3 APPEAR-C3G study, on which patients with C3G treated with the drug on top of supportive care experienced clinically meaningful ...

Researchers at Baylor College of Medicine and the Jan and Dan Duncan Neurological Research Institute at Texas Children’s ...

The novel PDE10A inhibitor CPL'36 offers a new mechanism of action and is both safe and effective for acute exacerbations of schizophrenia, new research suggests.

The opioid crisis has made it even more urgent to come up with novel approaches to treating suffering. Finally there’s ...

There are over 20,000 prescription drugs approved by the Food and Drug Administration (FDA). The number of medical ...